School of Regenerative Medicine, Manipal Academy of Higher Education, Bangalore, Karnataka, India.
Department of Physiology, Melaka Manipal Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India.
Curr Gene Ther. 2018;18(5):307-323. doi: 10.2174/1566523218666180913152615.
INTRODUCTION: Mesenchymal Stem Cell (MSC) therapy in recent years has gained significant attention. Though the functional outcomes following MSC therapy for neurodegenerative diseases are convincing, various mechanisms for the functional recovery are being debated. Nevertheless, recent studies convincingly demonstrated that recovery following MSC therapy could be reiterated with MSC secretome per se thereby shifting the dogma from cell therapy to cell "based" therapy. In addition to various functional proteins, stem cell secretome also includes extracellular membrane vesicles like exosomes. Exosomes which are of "Nano" size have attracted significant interest as they can pass through the bloodbrain barrier far easily than macro size cells or growth factors. Exosomes act as a cargo between cells to bring about significant alterations in target cells. As the importance of exosomes is getting unveil, it is imperial to carry out a comprehensive study to evaluate the neuroprotective potential of exosomes as compared to conventional co-culture or total condition medium treatments. OBJECTIVE: Thus, the present study is designed to compare the neuroprotective potential of MSC derived exosomes with MSC-condition medium or neuron-MSC-co-culture system against kainic acid induced excitotoxicity in in vitro condition. The study also aims at comparing the neuroprotective efficacy of exosomes/condition medium/co-culture of two MSC viz., neural crest derived human Dental Pulp Stem Cells (hDPSC) and human Bone-Marrow Mesenchymal Stem Cells (hBM-MSC) to identify the appropriate MSC source for treating neurodegenerative diseases. RESULT: Our results demonstrated that neuroprotective efficacy of MSC-exosomes is as efficient as MSC-condition medium or neuron-MSC co-culture system and treating degenerating hippocampal neurons with all three MSC based approaches could up-regulate host's endogenous growth factor expressions and prevent apoptosis by activating cell survival PI3K-B-cell lymphoma-2 (Bcl-2) pathway. CONCLUSION: Thus, the current study highlights the possibilities of treating neurodegenerative diseases with "Nano" size exosomes as opposed to transplanting billions of stem cells which inherit several disadvantages.
简介:近年来,间充质干细胞(MSC)疗法受到了广泛关注。尽管 MSC 疗法治疗神经退行性疾病的功能结果令人信服,但对于功能恢复的各种机制仍存在争议。然而,最近的研究令人信服地表明,MSC 分泌组本身就可以重复 MSC 治疗后的恢复,从而将治疗模式从细胞治疗转变为基于细胞的治疗。除了各种功能蛋白外,干细胞分泌组还包括外泌体等细胞外膜囊泡。外泌体的“纳米”大小引起了人们的极大兴趣,因为它们比大尺寸细胞或生长因子更容易穿过血脑屏障。外泌体作为细胞之间的载体,使靶细胞发生显著变化。随着对外泌体重要性的认识不断深入,进行一项全面的研究来评估外泌体的神经保护潜力,与传统的共培养或总条件培养基处理相比,是至关重要的。
目的:因此,本研究旨在比较 MSC 来源的外泌体与 MSC 条件培养基或神经元-MSC 共培养系统在体外对抗 KA 诱导的兴奋性毒性的神经保护潜力。该研究还旨在比较两种 MSC(神经嵴来源的人牙髓干细胞(hDPSC)和人骨髓间充质干细胞(hBM-MSC)的外泌体/条件培养基/共培养的神经保护效果,以确定用于治疗神经退行性疾病的合适 MSC 来源。
结果:我们的结果表明,MSC 外泌体的神经保护效果与 MSC 条件培养基或神经元-MSC 共培养系统一样有效,用所有三种基于 MSC 的方法治疗退化的海马神经元可以上调宿主内源性生长因子的表达,并通过激活细胞存活 PI3K-B 细胞淋巴瘤-2(Bcl-2)途径来防止细胞凋亡。
结论:因此,本研究强调了使用“纳米”大小的外泌体治疗神经退行性疾病的可能性,而不是移植数十亿继承了许多缺点的干细胞。
Int J Mol Sci. 2021-11-6
Biomaterials. 2019-1-9
Int J Oral Sci. 2025-6-16
Pharmaceutics. 2025-1-22
Anat Sci Int. 2025-1
Biomolecules. 2024-3-11